{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:35:47Z","timestamp":1791200147505,"version":"4.2.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T00:00:00Z","timestamp":1260403200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p>Interferon lambdas (IFN\u2010\u03bb) are Type III interferons with biological activity, including induction of antiviral genes, similar to Type I IFNs, but signal through a distinct receptor complex. The expression pattern for the IFN\u2010\u03bb receptor is more cell specific than the widely distributed IFN\u2010\u03b1 receptor, suggesting <jats:italic>in vivo<\/jats:italic>, IFN\u2010\u03bb may have fewer side effects than IFN\u2010\u03b1, such as less hematologic toxicities. A PEGylated form of IFN\u2010\u03bb (PEG\u2010rIL\u201029) was well tolerated in animals and did not result in hematologic toxicity. Clinical data from initial studies of PEG\u2010rIL\u201029 has demonstrated antiviral effects in patients with hepatitis C without producing hematologic toxicity. These preclinical and early clinical data support PEG\u2010rIL\u201029 as a potential new therapeutic agent for treatment of patients with hepatitis C.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2009.05241.x","type":"journal-article","created":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T18:01:44Z","timestamp":1260468104000},"page":"80-87","source":"Crossref","is-referenced-by-count":55,"title":["Interferon Lambda as a Potential New Therapeutic for Hepatitis C"],"prefix":"10.1111","volume":"1182","author":[{"given":"Dennis M.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Klucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana F.","family":"Hausman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,14]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni873"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni875"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.26.373"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152306778017656"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1208761"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.778-809.2001"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.227"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700135"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2005.04.003"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.6.3851-3854.2005"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-80"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.9.4501-4509.2006"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21312"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000017"},{"key":"e_1_2_7_16_2","first-page":"1","volume-title":"Summary Basis of Approval for Peg\u2010Intron (Peginterferon alfa 2b), Toxicologist's Review","year":"2001"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199918010-00004"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80078-1"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199304000-00006"},{"issue":"2","key":"e_1_2_7_20_2","first-page":"71","article-title":"Abstract 67: A phase 1, randomized, blinded, placebo\u2010controlled, single\u2010dose, dose\u2010escalation study of PEG\u2010interferon lamda (PEG\u2010rIL\u201029) in healthy subjects HEP DART 2007","volume":"3","author":"Hausman D.F.","year":"2007","journal-title":"Frontiers in Drug Development for Viral Hepatitis"},{"issue":"4","key":"e_1_2_7_21_2","first-page":"385A","article-title":"Phase 1b dose\u2010escalation study of PEG\u2010interferon\u2010lambda (PEG\u2010rIL\u201029) in relapsed chronic hepatitis C patients; abstract 170","volume":"48","author":"Lawitz E.","year":"2008","journal-title":"Hepatology"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2009.05241.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2009.05241.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T21:55:28Z","timestamp":1695678928000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2009.05241.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1749-6632.2009.05241.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05241.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}